Dr. Bear is an internationally recognized expert on how experience modifies synaptic communication between neurons in the brain. Discoveries in his lab led to the key insight that multiple aspects of Fragile X Syndrome could arise from excessive activation of a biochemical pathway downstream of metabotropic glutamate receptor 5. Based upon these insights, Seaside Therapeutics licensed a novel series of compounds targeting this receptor. Dr. Bear continues to closely advise the Company. Prior to joining the Picower Institute, Dr. Bear was the Sidney A. and Dorothea Doctors Fox Professor of Neuroscience at Brown University. He was a founder of Sention and served as Chair of Sention's Scientific Advisory Board from 1999 to 2005. Among numerous honors, Bear received the Society for Neuroscience Young Investigator Award in 1993, has been an Investigator of the Howard Hughes Medical Institute since 1994, was elected as a Fellow of the American Academy of Arts and Sciences in 2004 and received the William Rosen Research Award from the National Fragile X Foundation in 2006. Dr. Bear received his PhD from Brown University and was a Fellow at the Max-Planck-Institut fur Hirnforschung, Frankfur